Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Kolltan in-licenses cancer mAb from MedImmune

Executive Summary

Kolltan Pharmaceuticals Inc. (developing drugs that modulate receptor tyrosine kinase (RTK) function to treat cancer and other serious diseases) licensed rights to MedImmune LLC’s preclinical HER-3 (ErbB3) inhibitor. Kolltan plans to have the candidate in Phase I trials in early 2014.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies

UsernamePublicRestriction

Register